[Anemia as a risk factor for CKD and CVD]

Area of Science:

• Nephrology
• Cardiology
• Hematology

Context:

• Chronic kidney disease (CKD) is a significant risk factor for end-stage renal disease (ESRD) and cardiovascular disease (CVD).
• Anemia is a common complication of CKD, contributing to a vicious cycle that worsens both kidney and cardiac function, termed Cardio-Renal Anemia (CRA) syndrome.
• Erythropoietin stimulating agents (ESAs) are used to treat renal anemia, aiming to improve quality of life and reduce mortality.

Purpose:

• To evaluate the efficacy of early ESA treatment targeting near-normal hemoglobin levels in reducing cardiovascular events in pre-dialysis CKD patients.
• To investigate the impact of different hemoglobin targets in ESA therapy on cardiovascular outcomes.

Summary:

• Two large randomized trials, CREATE and CHOIR, investigated early ESA treatment and higher hemoglobin targets in pre-dialysis CKD patients.
• These studies found that targeting near-normal hemoglobin levels did not reduce cardiovascular events compared to targeting sub-normal levels.
• Debate exists regarding baseline patient characteristics, particularly high cardiovascular comorbidity, influencing these findings.

Impact:

• The findings challenge the previous understanding of optimal hemoglobin targets for ESA treatment in CKD.
• Further research is required to establish appropriate hemoglobin level targets for ESA therapy in CKD patients to balance benefits and risks.
• This research has implications for clinical guidelines and patient management strategies regarding anemia treatment in chronic kidney disease.